Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIPO-202 for Reduction of Submental Subcutaneous Fat
NCT03005717Phase 2Completed
- Sponsor
- Neothetics
- Start
- Dec 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of salmeterol in submental fat (3 arms), sponsored by Neothetics. Primary endpoints: Number of subjects with adverse events at 12 weeks, Number of subjects with abnormal post baseline shifts in laboratory results at 12 weeks and 3 more. Started Dec 2016; status: completed.
02
Drugs
salmeterol
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT03005717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005717.